David Nemazee

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4678982/publications.pdf

Version: 2024-02-01

107 papers	12,148 citations	38742 50 h-index	31849 101 g-index
139 all docs	139 docs citations	139 times ranked	13765 citing authors

#	Article	IF	Citations
1	A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies. Nature Communications, 2022, 13, 462.	12.8	17
2	A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. Science Translational Medicine, 2022, 14, eabi9215.	12.4	123
3	In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice. Nature Biotechnology, 2022, 40, 1241-1249.	17.5	29
4	A broad and potent neutralization epitope in SARS-related coronaviruses. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	34
5	Broadly neutralizing antibodies target the coronavirus fusion peptide. Science, 2022, 377, 728-735.	12.6	111
6	Commercial Serology Assays Predict Neutralization Activity against SARS-CoV-2. Clinical Chemistry, 2021, 67, 404-414.	3.2	58
7	Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science, 2021, 371, 823-829.	12.6	285
8	Natural history of MZ B cells. Journal of Experimental Medicine, 2021, 218, .	8.5	11
9	Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. Nature Communications, 2021, 12, 2938.	12.8	219
10	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science, 2021, 373, 818-823.	12.6	309
11	A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. Cell Host and Microbe, 2021, 29, 806-818.e6.	11.0	49
12	A Rapid Assay for SARS-CoV-2 Neutralizing Antibodies That Is Insensitive to Antiretroviral Drugs. Journal of Immunology, 2021, 207, 344-351.	0.8	5
13	SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses. journal of applied laboratory medicine, The, 2021, 6, 1109-1122.	1.3	24
14	Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. Science Translational Medicine, 2021, 13, eabj5413.	12.4	79
15	Cleavage of DNA and RNA by PLD3 and PLD4 limits autoinflammatory triggering by multiple sensors. Nature Communications, 2021, 12, 5874.	12.8	21
16	Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science, 2020, 370, 1089-1094.	12.6	290
17	Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells. Nature Communications, 2020, 11, 5850.	12.8	38
18	Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens. PLoS Pathogens, 2020, 16, e1008665.	4.7	52

#	Article	IF	Citations
19	B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 22920-22931.	7.1	42
20	MicroRNA control of B cell tolerance, autoimmunity and cancer. Seminars in Cancer Biology, 2020, 64, 102-107.	9.6	23
21	Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science, 2020, 369, 956-963.	12.6	1,287
22	Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science, 2020, 369, 731-736.	12.6	534
23	Prediabetes Induced by a Single Autoimmune B Cell Clone. Frontiers in Immunology, 2020, 11, 1073.	4.8	3
24	Induction of Cross-Reactive and Protective Antibody Responses After DNA Vaccination With MHCII-Targeted Stem Domain From Influenza Hemagglutinin. Frontiers in Immunology, 2020, 11, 431.	4.8	4
25	A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. PLoS Pathogens, 2020, 16, e1009089.	4.7	55
26	Title is missing!. , 2020, 16, e1008665.		0
27	Title is missing!. , 2020, 16, e1008665.		0
28	Title is missing!. , 2020, 16, e1008665.		0
29	Title is missing!. , 2020, 16, e1008665.		0
30	Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes. Journal of Experimental Medicine, 2019, 216, 2331-2347.	8.5	13
31	Activated protein C ameliorates chronic graft-versus-host disease by PAR1-dependent biased cell signaling on T cells. Blood, 2019, 134, 776-781.	1.4	12
32	Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles. Molecular Therapy, 2019, 27, 2080-2090.	8.2	58
33	B Cells Carrying Antigen Receptors Against Microbes as Tools for Vaccine Discovery and Design. Current Topics in Microbiology and Immunology, 2019, 428, 165-180.	1.1	0
34	Reprogramming the antigen specificity of B cells using genome-editing technologies. ELife, 2019, 8, .	6.0	69
35	Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens. Immunity, 2018, 48, 133-146.e6.	14.3	274
36	Generation of T follicular helper cells inÂvitro: requirement for <scp>B</scp>â€cell receptor crossâ€linking and cognate Bâ€•and Tâ€cell interaction. Immunology, 2018, 153, 214-224.	4.4	18

#	Article	IF	Citations
37	HIV-1 vaccine design through minimizing envelope metastability. Science Advances, 2018, 4, eaau6769.	10.3	75
38	PLD3 and spinocerebellar ataxia. Brain, 2018, 141, e78-e78.	7.6	11
39	PLD3 and PLD4 are single-stranded acid exonucleases that regulate endosomal nucleic-acid sensing. Nature Immunology, 2018, 19, 942-953.	14.5	88
40	The Bacterial Peptidoglycan-Sensing Molecules NOD1 and NOD2 Promote CD8+Thymocyte Selection. Journal of Immunology, 2017, 198, 2649-2660.	0.8	31
41	Mechanisms of central tolerance for B cells. Nature Reviews Immunology, 2017, 17, 281-294.	22.7	316
42	Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo. Journal of Experimental Medicine, 2017, 214, 2573-2590.	8.5	151
43	Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. Nature Communications, 2016, 7, 12041.	12.8	146
44	Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies. Cell, 2016, 166, 1459-1470.e11.	28.9	230
45	High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. Cell Reports, 2016, 15, 1986-1999.	6.4	127
46	Regulation of B-cell development and tolerance by different members of the miR-17â^¼92 family microRNAs. Nature Communications, 2016, 7, 12207.	12.8	65
47	The microRNA miR-148a functions as a critical regulator of B cell tolerance and autoimmunity. Nature Immunology, 2016, 17, 433-440.	14.5	123
48	Receptor editing and genetic variability in human autoreactive B cells. Journal of Experimental Medicine, 2016, 213, 93-108.	8.5	37
49	Central B Cell Tolerance. , 2016, , 78-82.		0
50	Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science, 2015, 349, 156-161.	12.6	358
51	Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors. Science, 2013, 340, 711-716.	12.6	680
52	2G12-Expressing B Cell Lines May Aid in HIV Carbohydrate Vaccine Design Strategies. Journal of Virology, 2013, 87, 2234-2241.	3.4	18
53	Immune Tolerance Negatively Regulates B Cells in Knock-In Mice Expressing Broadly Neutralizing HIV Antibody 4E10. Journal of Immunology, 2013, 191, 3186-3191.	0.8	103
54	B Cells from Knock-in Mice Expressing Broadly Neutralizing HIV Antibody b12 Carry an Innocuous B Cell Receptor Responsive to HIV Vaccine Candidates. Journal of Immunology, 2013, 191, 3179-3185.	0.8	41

#	Article	IF	Citations
55	Skewed Primary Igĵº Repertoire and Vâ€“J Joining in C57BL/6 Mice: Implications for Recombination Accessibility and Receptor Editing. Journal of Immunology, 2012, 188, 2305-2315.	0.8	71
56	Anti-HIV B Cell Lines as Candidate Vaccine Biosensors. Journal of Immunology, 2012, 189, 4816-4824.	0.8	57
57	The P4-type ATPase ATP11C is essential for B lymphopoiesis in adult bone marrow. Nature Immunology, 2011, 12, 434-440.	14.5	85
58	Liver-expressed Igĵº superantigen induces tolerance of polyclonal B cells by clonal deletion not ĵº to ĵ» receptor editing. Journal of Experimental Medicine, 2011, 208, 617-629.	8.5	17
59	Negative Selection by IgM Superantigen Defines a B Cell Central Tolerance Compartment and Reveals Mutations Allowing Escape. Journal of Immunology, 2011, 187, 5596-5605.	0.8	25
60	Decoration of T-independent antigen with ligands for CD22 and Siglec-G can suppress immunity and induce B cell tolerance in vivo. Journal of Experimental Medicine, 2010, 207, 173-187.	8.5	150
61	A mutation of Ikbkg causes immune deficiency without impairing degradation of IÂBÂ. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 3046-3051.	7.1	21
62	Regulation of the B Cell Receptor Repertoire and Self-Reactivity by BAFF. Journal of Immunology, 2010, 185, 4128-4136.	0.8	85
63	Peripheral B Cell Tolerance and Function in Transgenic Mice Expressing an IgD Superantigen. Journal of Immunology, 2010, 184, 4143-4158.	0.8	19
64	Deletion of IgG-Switched Autoreactive B Cells and Defects in Faslpr Lupus Mice. Journal of Immunology, 2010, 185, 1015-1027.	0.8	25
65	Suppression of IgE B Cells and IgE Binding to FcĴµRI by Gene Therapy with Single-Chain Anti-IgE. Journal of Immunology, 2009, 182, 8110-8117.	0.8	18
66	Distinct roles for E12 and E47 in B cell specification and the sequential rearrangement of immunoglobulin light chain loci. Journal of Experimental Medicine, 2009, 206, 2271-2284.	8.5	91
67	Rearrangement of Mouse Immunoglobulin Kappa Deleting Element Recombining Sequence Promotes Immune Tolerance and Lambda B Cell Production. Immunity, 2008, 28, 161-170.	14.3	46
68	FGD2, a CDC42-specific Exchange Factor Expressed by Antigen-presenting Cells, Localizes to Early Endosomes and Active Membrane Ruffles. Journal of Biological Chemistry, 2008, 283, 34002-34012.	3.4	46
69	Basal B Cell Receptor-Directed Phosphatidylinositol 3-Kinase Signaling Turns Off RAGs and Promotes B Cell-Positive Selection. Journal of Immunology, 2007, 178, 6332-6341.	0.8	92
70	Reduced receptor editing in lupus-prone MRL/lpr mice. Journal of Experimental Medicine, 2007, 204, 2853-2864.	8.5	36
71	Polyspecificity of T cell and B cell receptor recognition. Seminars in Immunology, 2007, 19, 216-224.	5.6	194
72	Role of RS/ĵºDE in B Cell Receptor Editing. , 2007, 596, 169-172.		1

#	Article	IF	Citations
73	Receptor editing in lymphocyte development and central tolerance. Nature Reviews Immunology, 2006, 6, 728-740.	22.7	310
74	Effect of cell:cell competition and BAFF expression on peripheral B cell tolerance and B-1 cell survival in transgenic mice expressing a low level of IgÎº-reactive macroself antigen. European Journal of Immunology, 2006, 36, 985-996.	2.9	15
75	Paucity of V-D-D-J Rearrangements and VH Replacement Events in Lupus Prone and Nonautoimmune TdTâ^'/â^' and TdT+/+ Mice. Journal of Immunology, 2006, 177, 1120-1128.	0.8	29
76	Split Tolerance in Peripheral B Cell Subsets in Mice Expressing a Low Level of IgÎº-Reactive Ligand. Journal of Immunology, 2006, 176, 939-948.	0.8	16
77	Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor Signaling. Science, 2006, 314, 1936-1938.	12.6	545
78	An immunoglobulin CÎº-reactive single chain antibody fusion protein induces tolerance through receptor editing in a normal polyclonal immune system. Journal of Experimental Medicine, 2005, 201, 817-828.	8.5	61
79	A Role for Nuclear Factor Kappa B/Rel Transcription Factors in the Regulation of the Recombinase Activator Genes. Immunity, 2005, 22, 519-531.	14.3	80
80	Peripheral B lymphocyte tolerance. Keio Journal of Medicine, 2004, 53, 151-158.	1.1	2
81	Tolerance-induced receptor selection: scope, sensitivity, locus specificity, and relationship to lymphocyte-positive selection. Immunological Reviews, 2004, 197, 219-230.	6.0	19
82	The scope of receptor editing and its association with autoimmunity. Current Opinion in Immunology, 2004, 16, 808-814.	5.5	46
83	Antigen receptor selection by editing or downregulation of V(D)J recombination. Current Opinion in Immunology, 2003, 15, 182-189.	5.5	68
84	Haplotype exclusion and receptor editing: irreconcilable differences?. Seminars in Immunology, 2002, 14, 191-198.	5.6	3
85	Do B Cells Take Advantage of 'Missing Selfï¿½ Recognition?. , 2002, 6, 245-264.		3
86	Role of receptor editing and revision in shaping the B and T lymphocyte repertoire. Life Sciences, 2001, 69, 1105-1113.	4.3	35
87	Contribution of Receptor Editing to the Antibody Repertoire. Science, 2001, 291, 1541-1544.	12.6	277
88	B cell clonal elimination induced by membrane-bound self-antigen may require repeated antigen encounter or cell competition. European Journal of Immunology, 2000, 30, 689-696.	2.9	25
89	Role of B Cell Antigen Receptor in Regulation of V(D)J Recombination and Cell Survival. Immunologic Research, 2000, 21, 259-264.	2.9	10
90	T Cell-Independent Rescue of B Lymphocytes from Peripheral Immune Tolerance. Science, 2000, 287, 2501-2503.	12.6	69

#	Article	IF	Citations
91	A VH11Vî9 B Cell Antigen Receptor Drives Generation of CD5+ B Cells Both In Vivo and In Vitro. Journal of Immunology, 2000, 164, 4586-4593.	0.8	72
92	Revising B Cell Receptors. Journal of Experimental Medicine, 2000, 191, 1813-1818.	8.5	239
93	Receptor Selection in B and T Lymphocytes. Annual Review of Immunology, 2000, 18, 19-51.	21.8	206
94	Receptor editing: Genetic reprogramming of autoreactive lymphocytes. Cell Biochemistry and Biophysics, 1999, 31, 81-88.	1.8	3
95	V(D)J recombinase induction in splenic B lymphocytes is inhibited by antigen-receptor signalling. Nature, 1998, 394, 292-295.	27.8	112
96	Receptor editing and commitment in B lymphocytes. Current Opinion in Immunology, 1998, 10, 208-213.	5.5	52
97	Developmental Regulation of B Lymphocyte Immune Tolerance Compartmentalizes Clonal Selection from Receptor Selection. Cell, 1998, 92, 173-182.	28.9	214
98	Receptor Editing Occurs Frequently during Normal B Cell Development. Journal of Experimental Medicine, 1998, 188, 1231-1238.	8.5	179
99	Efficient Peripheral Clonal Elimination of B Lymphocytes in MRL/lpr Mice Bearing Autoantibody Transgenes. Journal of Experimental Medicine, 1998, 188, 909-917.	8.5	46
100	Anti-laminin Reactivity and Glomerular Immune Deposition by in Vitro Recombinant Antibodies. Autoimmunity, 1997, 26, 231-243.	2.6	12
101	V(D)J Recombination in Mature B Cells: A Mechanism for Altering Antibody Responses. Science, 1997, 278, 298-301.	12.6	248
102	BCR Ligation Induces Receptor Editing in IgM+IgDâ˚' Bone Marrow B Cells In Vitro. Immunity, 1997, 6, 429-436.	14.3	169
103	Receptor Editing in a Transgenic Mouse Model: Site, Efficiency, and Role in B Cell Tolerance and Antibody Diversification. Immunity, 1997, 7, 765-775.	14.3	268
104	Enforced Bcl-2 Expression Inhibits Antigen-mediated Clonal Elimination of Peripheral B Cells in an Antigen Doseâ€"dependent Manner and Promotes Receptor Editing in Autoreactive, Immature B Cells. Journal of Experimental Medicine, 1997, 186, 1513-1522.	8.5	123
105	Can receptor editing play an important role in normal B-cell development?. Journal of Autoimmunity, 1996, 9, 259-261.	6.5	9
106	Antigen receptor â€˜capacityâ€™ and the sensitivity of self-tolerance. Trends in Immunology, 1996, 17, 25-29.	7.5	74
107	Peripheral deletion of self-reactive B cells. Nature, 1991, 354, 308-311.	27.8	348